Seminars in Oncology
Volume 34, Issue 5 , Pages 428-434, October 2007

Cowden Syndrome

  • Shanna Gustafson

      Affiliations

    • Center for Personalized Genetic Healthcare, Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • ,
  • Kevin M. Zbuk

      Affiliations

    • Center for Personalized Genetic Healthcare, Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • ,
  • Cheryl Scacheri

      Affiliations

    • Center for Personalized Genetic Healthcare, Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • ,
  • Charis Eng

      Affiliations

    • Center for Personalized Genetic Healthcare, Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH.
    • Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Cleveland, OH.
    • Department of Genetics, Case Western Reserve University School of Medicine, Cleveland, OH.
    • Corresponding Author InformationAddress correspondence to Charis Eng, MD, PhD, FACP, Genomic Medicine Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, NE-50, Cleveland OH, 44195, USA.
    • C.E. is a recipient of the Doris Duke Distinguished Clinical Scientist Award.

Cowden syndrome (CS), due to germline mutations of the PTEN tumor-suppressor gene, is an often overlooked cancer predisposition syndrome associated with an increased risk of breast, thyroid, and endometrial cancers, as well as benign manifestations. Germline PTEN mutations also are associated with syndromes that have not been historically connected to an increase in risk for malignancy. These disorders include Bannayan-Riley-Ruvalcaba syndrome (BRRS), Proteus syndrome (PS), and Proteus-like syndrome (PSL). These syndromes can be described under the umbrella of PTEN hamartoma tumor syndrome (PHTS). As one would expect in allelic disorders, there is broad phenotypic overlap in the PHTS; however, the syndromes are clinically distinct. As additional information is discovered about new syndromes of cancer predisposition and their concordant genes, oncologists and allied healthcare providers must maintain vigilance to appropriately identify, and screen, individuals at an increased risk. Although CS is the only PHTS with a clearly documented predisposition to malignancies, pending further data, for precautionary reasons all individuals with a germline PTEN mutation are recommended to follow the cancer surveillance recommendations for CS.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(07)00146-7

doi:10.1053/j.seminoncol.2007.07.009

Seminars in Oncology
Volume 34, Issue 5 , Pages 428-434, October 2007